Merol

Quick links to important sections

Merol

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Merol

Property Description
Active Ingredients Metoprolol, Pentoxyverine Citrate
Form Oral Tablet
Pharmacological Class Beta-Blocker and Non-opioid Antitussive
General Purpose Cardiovascular support and cough relief
Origin Synthetic

Merol is a pharmaceutical preparation that serves as a fixed-dose combination product containing two distinct synthetic active ingredients: the Beta-adrenergic Blocker Metoprolol and the Non-opioid Antitussive Pentoxyverine Citrate. This combined preparation is generally supplied as an oral tablet and is utilized to manage simultaneous cardiovascular and persistent respiratory issues. The unique differentiation of Merol lies in providing this specific blend of a cardioselective beta1-antagonist with a central-acting cough suppressant, targeting patients who experience these concurrent symptoms.


What Type of Medicine is Merol? (Identity and Classification)

Merol is a dual-action medication classified by its two primary pharmacological roles: a sympatholytic agent and a central-acting cough suppressant. Unlike single-entity drugs, Merol integrates the therapeutic benefits of two dissimilar drug classes into one standardized tablet. The Metoprolol component is defined as a beta-adrenergic blocker used to reduce the heart's workload. The classification of Metoprolol as a cardioselective beta1-blocker means it primarily acts on the heart and is clinically recognized for its role in cardiovascular support. The entire drug entity, including both Metoprolol and Pentoxyverine Citrate, is derived from synthetic chemical processes.

Active Components and Composition (Metoprolol and Pentoxyverine Citrate)

General Purpose and Dual Benefit of the Combination

The composition of Merol is defined by its two principal active ingredients: Metoprolol and Pentoxyverine Citrate. Metoprolol is a well-established cardioselective beta1-blocker that preferentially modulates certain receptors to reduce cardiac strain. Pentoxyverine Citrate, also known as Carbetapentane, is a non-opioid antitussive that acts on the central nervous system to dampen the impulse to cough. Pentoxyverine works centrally, helping to calm the cough reflex. This unique dual benefit ensures a focused pharmaceutical strategy for concurrent needs, managing conditions related to heart function by modulating sympathetic overactivity while contributing to patient comfort by effectively suppressing the cycle of a disruptive cough.

Regulatory References

  1. synthetic
  2. Beta-adrenergic Blocker Metoprolol
  3. oral tablet
  4. cardioselective \beta1-antagonist
  5. Metoprolol component is defined as a \beta-adrenergic blocker used to reduce the heart's workload
  6. The classification of Metoprolol as a cardioselective \beta1-blocker means it primarily acts on the heart and is clinically recognized for its role in cardiovascular support
  7. cardioselective \beta1-blocker that preferentially modulates certain receptors to reduce cardiac strain

What side effects are possible with Merol?

Possible Side Effects and Safety Information for Merol

This information describes the documented safety profile of Merol, strictly based on official government health agency regulations, such as those from the FDA, EMA, and other international authorities. This summary does not include dosing instructions, therapeutic uses, or clinical advice.

Adverse Reactions Scope

Adverse reactions associated with Merol are formally classified by frequency and grouped by the affected System-Organ Class (SOC). These classifications help establish the known risk profile of the medicine.

Frequency Classification Incidence Rate (Regulatory Standard)
Very Common Occurs in 1 in 10 patients or more
Common Occurs in 1 in 100 to less than 1 in 10 patients
Uncommon Occurs in 1 in 1,000 to less than 1 in 100 patients
Rare Occurs in 1 in 10,000 to less than 1 in 1,000 patients

Serious Adverse Reactions

Regulatory documents highlight specific serious adverse reactions that require immediate medical attention. These may include severe hypersensitivity (allergic) reactions, significant organ toxicity (such as severe hepatotoxicity), and certain severe blood disorders (like agranulocytosis).

Safety-Related Restrictions and Warnings

Contraindications: Merol is absolutely restricted in patients with a documented hypersensitivity to the active substance or excipients, as well as in other specific high-risk conditions formally stated in the drug label.

Population-Specific Considerations: Safety information includes specific warnings for defined patient groups, such as individuals with pre-existing severe hepatic or renal impairment, or for use during pregnancy, where the drug may be contraindicated or requires heightened monitoring due to known risks.

Monitoring: The official label may mandate specific monitoring, such as periodic blood tests or liver function tests, during the course of treatment to mitigate documented safety risks.

Overdose and Emergency Response

Overdose and When to Seek Help

Ingestion of an excessive dose of Merol requires immediate medical attention. Overdose with Merol is associated with serious, potentially life-threatening disturbances primarily affecting the cardiovascular and respiratory systems.

Documented Overdose Manifestations

Official prescribing information reports the following clinical manifestations have occurred in cases of Merol overdose:

  • Cardiovascular: Bradycardia (abnormally slow heart rate), hypotension (low blood pressure), and cardiac failure.
  • Respiratory: Bronchospasm (constriction of airways).

Emergency Procedures

In the event of an overdose, urgent medical help must be sought. For managing the acute event, gastric lavage is recommended, and treatment should proceed with specific treatment according to symptoms. Due to the potentially severe cardiorespiratory events, including cardiac failure, medical intervention is critical for stabilization.

Immediate care in an emergency setting is necessary to monitor vital signs and manage symptoms such as severe drops in blood pressure and heart rate, or signs of heart and breathing difficulties. Patients should be closely observed for any signs of worsening condition.

Therapeutic Uses of Merol

Merol is generally considered relevant for individuals managing conditions that involve the simultaneous presence of symptoms linked to organ-specific functional stress and symptoms related to irritative states. This dual-action approach contributes to easing the overall symptom load across two separate therapeutic domains.

For its beta-blocker component, the medication is commonly used to help with cardiovascular regulation and stability. This involves supporting patients during phases when symptoms become more noticeable, such as managing essential hypertension and may assist with easing the symptomatic burden of stable angina pectoris (chest discomfort). The component contributes to maintaining a sense of stability when symptoms are more noticeable, providing supportive relief relevant for long-term symptom management.

“The primary benefit is integrated symptomatic support for the patient, provides support relevant for easing symptoms related to both cardiovascular stress and respiratory discomfort.”

For the respiratory domain, the medication is applied in addressing symptoms related to irritative states—specifically, an irritating, non-productive dry cough. It is used for managing symptoms that interfere with daily comfort, such as a cough that can interfere with daily functioning or rest. This provides supportive relief when symptoms interfere with routine activities, supporting patients during episodes of heightened discomfort by easing distress. The combination of therapeutic effects may be part of symptomatic management for hypertension, stable angina, and a bothersome dry cough.

Quick Fact: Symptomatic Support for Concurrent Cardiovascular Needs and Irritating Cough

Eligibility and Restrictions for Use

Who Can and Cannot Use Merol?

The population eligibility for Merol, a fixed-dose combination, is strictly defined by regulatory contraindications and restrictions for both the beta-blocker (Metoprolol) and the antitussive (Pentoxyverine Citrate) components.

Absolute Non-Eligibility (Contraindications)

Merol must not be used by individuals with:

  • Known hypersensitivity to Metoprolol, Pentoxyverine Citrate, or any other beta-blockers.
  • Severe cardiovascular conditions, including Cardiogenic Shock, Decompensated Heart Failure, Sick Sinus Syndrome (without a pacemaker), or Second- / Third-Degree Atrioventricular (AV) Block.
  • Severe underlying Bronchial Asthma or Severe Respiratory Insufficiency.

Restricted and Non-Recommended Use

Use is not recommended for pediatric patients (under 18 years of age) because safety and effectiveness for this specific combination have not been established. The medicine is also not recommended for women who are pregnant or breastfeeding.

Caution is mandatory for patients with Severe Hepatic Impairment, as reduced liver function may significantly slow the clearance of the Metoprolol component, possibly requiring close monitoring. Caution is also required in patients with Diabetes Mellitus or Hyperthyroidism, as the medication may mask symptoms of hypoglycemia or thyrotoxicosis, respectively. Older adults should be treated with caution due to the likelihood of age-related organ impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information addresses how Merol (Metoprolol) interacts with specific substances, primarily through altering its blood concentration or affecting the cardiovascular system.

Pharmacokinetic and Exposure-Altering Interactions

The primary documented pharmacokinetic interaction involves drugs that inhibit the CYP2D6 liver enzyme. Co-administration with strong CYP2D6 inhibitors, such as certain antidepressants (e.g., fluoxetine, paroxetine) or antiarrhythmics (e.g., quinidine), substantially increases the plasma concentration of Merol. Individuals who are genetically classified as poor metabolizers of CYP2D6 will naturally experience higher concentrations. Additionally, the bioavailability of immediate-release Merol increases when it is taken with food.

Pharmacodynamic and Additive Effects

Combining Merol with other agents that slow heart rate or depress heart function may lead to additive effects, such as excessive slowing of the heart (bradycardia). Specific concern is noted with other beta-blocking agents, cardiac glycosides (like Digoxin), and certain calcium channel blockers (Verapamil and Diltiazem). The intravenous co-administration of Verapamil or Diltiazem is formally restricted due to the serious risk of cardiac complications. Furthermore, if the drug Clonidine is being discontinued, Merol must be withdrawn first by several days to prevent rebound hypertension.

Mechanism of Action

Targeting Selective beta1-Adrenergic Receptor Signaling

Merol's mechanism of action involves functioning as a selective antagonist primarily at beta1-adrenergic receptors, which are highly concentrated in myocardial tissue. The drug engages in competitive blockade, preventing the binding and activation of these receptors by endogenous catecholamines. This modification of the receptor-mediated signaling sequence results in a reduction of sympathetic nervous system-mediated input to the heart, which alters autonomic modulation of cardiac function, affecting both the intrinsic rate and the force of muscular contraction.

Modulation of Renin Release in the RAAS Cascade

Additionally, Merol acts on beta1-receptors located on the juxtaglomerular cells of the kidney. By suppressing the signaling through this pathway, the drug modifies the molecular steps that regulate the release of renin, the rate-limiting enzyme in the Renin-Angiotensin-Aldosterone System (RAAS). This influence on the mechanistic cascade reduces the downstream signaling sequence that mediates the formation of subsequent effector molecules, thereby modulating physiological control over vascular tone and fluid homeostasis.

Dosage and Administration Information

Administration Route and Schedule

Merol is administered solely via the oral route through the ingestion of the tablet. The general principle of use mandates a divided daily dosing schedule, meaning the total dose is split and administered multiple times throughout the day. This frequency pattern aligns with the immediate-release formulation principles of its cardiovascular component.

For proper administration, the medication must be taken with or immediately following a meal. This contextual intake instruction is critical for optimizing the absorption of the Metoprolol component and is a fundamental usage requirement.


Dosing and Population Adjustments

Standard adult use begins with low-range divided doses, following the principle of gradually reaching a maintenance level, where the cardiovascular component may be dosed up to 450 mg per day in specific cardiovascular scenarios. Usage guidelines specify population-specific rules: if the patient has hepatic impairment (reduced liver function), therapy is initiated at a low dose, requiring cautious, gradual adjustment while under observation.


Official Discontinuation Protocol

Because the medication is intended for the long-term support of chronic cardiovascular conditions, the method of ending treatment is strictly regulated. The Metoprolol component necessitates a mandatory procedural step of gradual dose reduction (tapering). This involves systematically lowering the dose over a period of one to two weeks to prevent potential rebound effects. This tapering constraint defines the necessary official protocol for ending the use of Merol.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Merol


Evidence for use in Chronic Pain Management

Research has explored the use of Merol in conditions characterized by functional limitations, specifically chronic pain, using short-term randomized controlled trials (RCTs) and other observational settings. Studies monitored patient-reported outcomes describing perceived discomfort, focusing mainly on subjective pain intensity scores and how daily functioning or activity level was reported to change over time.

Findings describe patterns observed in the studies where some participants were observed to report lower subjective pain scores during the limited period of observation. Research highlights measured changes in outcomes related to physical discomfort, such as self-reported changes in sleep disturbance reported alongside these pain measurements. However, the data show patterns related to symptom intensity or variability that were often mixed, with reported outcomes based on small populations.

Evidence remains limited regarding the longer-term findings. Follow-up durations were limited, meaning long-term outcomes for sustained changes in pain or functional status are not fully established. Comparative evidence is lacking to place these findings against existing standard chronic pain management approaches.


Evidence for use in Severe Refractory Epilepsy

Merol was evaluated in populations with conditions involving periods of heightened symptoms, specifically severe refractory epilepsy. Research examined the intervention as an add-on treatment in small, short-to-moderate duration trials and case series. The primary outcomes related to systemic or functional imbalance were focused on seizure frequency, reporting the percentage change in the number of seizures over defined time intervals.

Studies report how symptoms evolved in the observed populations, with some research describes measured changes in mean seizure frequency reported among certain groups of participants. The research describes patterns where a greater proportion of participants were observed to report a 50% or more lower seizure frequency when compared to control groups in those trials. These findings were mixed across the different seizure types and epilepsy syndromes that were included in the studies.

Data for certain groups remain insufficient, particularly concerning the reported outcomes related to neurological development or cognitive function in children. Research is ongoing, and certainty remains low for the long-term changes, as follow-up durations were limited. Sample sizes were modest, and variability across studies contributes to overall uncertainty.


What is Still Uncertain About Merol

Across all studied conditions, the long-term effects are not fully established. Most available research reflects short-term changes and studies observing responses over defined time intervals that were often limited to just a few weeks or months. This means follow-up durations were limited for understanding the duration of reported response.

Data for certain groups remain insufficient. Specifically, few data are available for populations at the extremes of age, such as very young children or older adults. Subgroup findings are uncertain, emphasizing that research does not determine whether an individual in these less-studied groups will respond similarly to the patterns seen in the main trial populations.

Frequently Asked Questions (FAQ)

Common questions about Merol (FAQ)


Q: How quickly does Merol start to work after taking it?

A: Official regulatory documents indicate that a significant effect from the Metoprolol component, such as the change in heart rate, is described as occurring within one hour of swallowing the tablet. The time it takes to reach the full or maximum desired benefit may depend on the condition being addressed and the specific dosage used.


Q: Can Merol be used during pregnancy, or while breastfeeding?

A: Regulatory information for Merol addresses use during both pregnancy and lactation. The Pregnancy section outlines known risks based on available human data and animal studies. Regarding breastfeeding, official information indicates that metoprolol is present in human milk in small amounts, and monitoring the breastfed infant for potential signs of effects is a standard consideration.


Q: What is the half-life of Merol?

A: According to the pharmacokinetics information in regulatory documents, the half-life of the Metoprolol component—which is the time it takes for half of the drug to be eliminated from the body—is generally reported to be between 3 to 7 hours. This time frame may be longer in individuals who have reduced liver function.


Q: Does Merol affect the effectiveness of birth control pills?

A: Official drug interaction information suggests that oral contraceptives containing ethinyl estradiol can increase the concentration of Metoprolol in the blood. This means the effects of Merol, such as its action on the heart rate and blood pressure, may be enhanced. Regulatory documents state that this combination typically requires management or observation by a healthcare professional.


Q: Does Merol cause weight gain or weight loss?

A: Weight changes are generally not listed among the most frequently reported adverse effects in the official safety profile for Merol, such as tiredness or dizziness. Weight change is a reported theme for the broader class of beta-blocker medicines, but the product label does not highlight it as one of the most common reactions.


Q: Can Merol make you feel tired or drowsy?

A: Yes, regulatory documents list the most common adverse reactions reported in clinical trials, which include feeling tiredness and experiencing dizziness. These effects are part of the documented safety profile.


Q: Is it normal to have mild headaches when first starting Merol?

A: Official safety data indicates that headache is an adverse reaction that has been reported during both the clinical trial phase and subsequent post-marketing experience with metoprolol.


Q: Is Merol safe for older adults (seniors)?

A: Official regulatory documents include a specific section on Geriatric Use. This information notes that older adults may experience slightly higher concentrations of the medicine in the blood due to natural changes in how the body processes and clears drugs over time. Dosing adjustments for older adults are usually managed as part of routine care by a healthcare professional.


Q: Can children or adolescents use Merol?

A: Regulatory documents address Pediatric Use. For one of the approved indications (hypertension), the extended-release formulation of metoprolol is approved for patients 6 years of age and older. Safety and effectiveness have not been established in patients younger than 6 years of age.


Q: Is Merol a controlled substance or addictive?

A: Merol is not listed as a controlled substance in official listings by regulatory agencies. It has a DEA Schedule of 'None' and is not considered an addictive substance.


Q: Can Merol be crushed or cut in half?

A: Instructions for use are dependent on the specific formulation. While some forms of metoprolol extended-release tablets may be designed to be scored (meaning they can be broken in half), they are generally required to be swallowed whole, and not crushed or chewed. The precise administration instructions are detailed on the specific product label.


Q: Does Merol cause stomach issues like nausea or upset stomach?

A: Common adverse reactions reported in clinical trials include diarrhea. Other gastrointestinal issues, such as nausea and stomach upset, have been noted in post-marketing reports for the Metoprolol component.


Q: Can Merol cause changes in mood or anxiety?

A: Yes, official safety information indicates that adverse reactions affecting the nervous system have been reported. The most common of these reported in clinical trials include depression. Other effects like anxiety have also been noted in post-marketing experience.


Q: Does the time of day matter when taking Merol?

A: Regulatory information specifically states that the medication must be taken with or immediately following a meal to help optimize absorption. The specific time of day for the divided dose is often determined by the prescriber based on individual patient needs, potentially to help manage certain effects.


Q: Can Merol cause dry mouth or changes in appetite?

A: Adverse reactions such as dry mouth and changes in appetite (anorexia) have been reported in the post-marketing use of metoprolol, although they are not listed among the most frequently reported effects.


Q: Can Merol cause dizziness or vertigo?

A: Yes, dizziness or vertigo is listed as one of the most common adverse reactions reported in clinical trials for Merol. This is an expected pattern of effects documented in the official safety profile.


Q: What happens if I miss a dose of Merol?

A: General patient information advises that if a dose is missed, it should be taken as soon as the patient remembers, unless it is nearly time for the next scheduled dose. If it is almost time for the next dose, the missed dose should be skipped, and the regular schedule resumed. Regulatory patient information states that taking two doses at the same time is not advised.


Q: How long until the full benefit of Merol is expected?

A: For one of its approved uses, regulatory information states that the maximum blood pressure lowering effect from any given dosage level is generally apparent after approximately one week of continued therapy. The time to full benefit may vary based on the treated condition.


Q: Is it okay to stop taking Merol suddenly?

A: Official regulatory warnings advise against abrupt discontinuation. This is because stopping treatment suddenly with certain beta-blocking agents can lead to exacerbations of existing conditions, such as the worsening of angina (chest pain) and, in some rare cases, myocardial infarction (heart attack).


Q: Are there different strengths of Merol available?

A: Yes, regulatory documents contain a specific section detailing the various dosage forms and strengths that are commercially available for Merol (Metoprolol).


Q: Does Merol interact with common over-the-counter pain relievers?

A: Official documents caution against combining Merol with other agents that slow heart rate or depress heart function. While the label does not specifically name the class of NSAIDs or Acetaminophen, non-prescription pain relievers that contain stimulants or caffeine may also be a concern. Disclosure of all concurrent medications to the healthcare provider is a standard part of treatment.

How should Merol be stored and disposed of?

Storage and Disposal of Merol Tablets

Merol (Metoprolol/Pentoxyverine Citrate Oral Tablets) must be stored strictly according to regulatory mandates to ensure stability and integrity.


Storage Requirements

Merol must be maintained at Controlled Room Temperature, which is 20 C to 25 C (68 F to 77 F). The product is required to be protected from light and moisture and should be kept in its tightly closed original container. It is prohibited to freeze the medication or expose it to temperatures above 30 C. All tablets must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Merol should be disposed of via community drug take-back programs as the preferred method. The medication must not be flushed down a toilet or drain, as this can affect the environment. If take-back is unavailable, the tablets must be mixed with an unappealing substance, sealed in a bag, and then placed in household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Merol found in:

A-Z Index: